- Research article
- Open Access
A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis
Arthritis Research & Therapyvolume 11, Article number: R180 (2009)
Chicken type II collagen (CCII) is a protein extracted from the cartilage of chicken breast and exhibits intriguing possibilities for the treatment of autoimmune diseases by inducing oral tolerance. A 24-week, double-blind, double-dummy, randomized, methotrexate (MTX)-controlled study was conducted to evaluate the efficacy and safety of CCII in the treatment of rheumatoid arthritis (RA).
Five hundred three RA patients were included in the study. Patients received either 0.1 mg daily of CCII (n = 326) or 10 mg once a week of MTX (n = 177) for 24 weeks. Each patient was evaluated for pain, morning stiffness, tender joint count, swollen joint count, health assessment questionnaire (HAQ), assessments by investigator and patient, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) by using the standard tools at baseline (week 0) and at weeks 12 and 24. Additionally, rheumatoid factor (RF) was evaluated at weeks 0 and 24. Measurement of a battery of biochemical parameters in serum, hematological parameters, and urine analysis was performed to evaluate the safety of CCII.
Four hundred fifty-four patients (94.43%) completed the 24-week follow-up. In both groups, there were decreases in pain, morning stiffness, tender joint count, swollen joint count, HAQ, and assessments by investigator and patient, and all differences were statistically significant. In the MTX group, ESR and CRP decreased. RF did not change in either group. At 24 weeks, 41.55% of patients in the CCII group and 57.86% in the MTX group met the American College of Rheumatology 20% improvement criteria (ACR-20) and 16.89% and 30.82%, respectively, met the ACR 50% improvement criteria (ACR-50). Both response rates for ACR-20 and ACR-50 in the CCII group were lower than those of the MTX group, and this difference was statistically significant (P < 0.05). The DAS28 (disease activity score using 28 joint counts) values of the two treatment groups were calculated, and there was a statistically significant difference between the two treatment groups (P < 0.05). Gastrointestinal complaints were common in both groups, but there were fewer and milder side effects in the CCII group than in the MTX group. The incidence of adverse events between the two groups was statistically significant (P < 0.05).
CCII is effective in the treatment of RA and is safe for human consumption. CCII exerts its beneficial effects by controlling inflammatory responses through inducing oral tolerance in RA patients.
Clinical trial registration number: ChiCTR-TRC-00000093.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pain, swelling, and stiffness of multiple joints. It is also a highly disabling disease that limits mobility, hampers work, and reduces quality of life. Chronic inflammation commonly results in progressive joint destruction, deformity, and loss of function. Complex immune mechanisms contribute to the pathology of RA [1, 2]. Current pharmacological strategies addressing mainly immune suppression and anti-inflammatory mechanisms have had limited success. Currently, most drugs for RA are steroids, non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying drugs, and biological agents. These therapies are associated with significant side effects with long administration, including anorexia, dyspepsy, suppression of the immune system non-specifically, and infections [3–5].
Recently, more and more oral tolerance mechanisms have been studied in the treatment of autoimmune diseases. Oral tolerance has posed intriguing possibilities for the treatment of autoimmune diseases, including RA. Oral tolerance is a state of systemic immune suppression to an antigen induced by oral feeding of the same antigen. Extensive research in this area over the past 10 years has led to the conclusion that two mechanisms are operative in the mediation of oral tolerance: active suppression and clonal anergy or deletion. A number of factors that determine which mechanisms of tolerance are operative have been identified: antigen dose, antigen form, and the timing of antigen administration [6, 7].
Oral administration of autoantigen has been shown to suppress a variety of autoimmune pathologies induced experimentally, including antigen-induced RA . Modulating the immune response to the autoantigen by oral tolerance may be a safer and more effective treatment. A number of candidate autoantigens have been identified in RA . Type II collagen (CII) is a major protein in articular cartilage and a potential autoantigen. Some RA patients demonstrate immunity against CII, and autoantibodies to CII have been detected in the sera of both pauciarticular-onset and systemic-onset RA patients . These data support the view that autoimmunity to an antigen such as CII in cartilage plays a major role in the pathogenesis of RA. In animal models, oral administration of CII prevents and reduces the severity of autoimmune diseases . Work from these animal models has recently been extended into human clinical trials of RA with differing degrees of success [12–14]. Hence, oral tolerance has been advocated as a treatment strategy for autoimmune diseases, including RA.
Investigators in our laboratory found that collagen-induced arthritis (CIA) could be established in Wistar rats, Kunming mice, and DBA/1 mice with chicken type II collagen (CCII) [15, 16]. Feeding CCII to rats by oral administration decreased the arthritis index. Meanwhile, cartilage degeneration, synovium hyperplasia, and inflammatory cell infiltration in the knee joints of mice and rats with CIA were suppressed by CCII [17, 18]. These experiments in rodents have provided the basis for human clinical trials. In a randomized, double-blind, multicenter, and controlled phase II clinical trial involving 236 patients with severe active RA, a decrease in the number of swollen joints and tender joints occurred in subjects fed CCII for 6 months. Meanwhile, CCII could reduce pain, morning stiffness, health assessment questionnaire (HAQ), and assessments by investigator and patient, and the incidence of adverse events of CCII was lower than that of methotrexate (MTX) . These results demonstrate clinical efficacy of an oral tolerance approach for RA. To evaluate the efficacy and safety of CCII in RA patients further, we treated two groups of RA patients with oral CCII or MTX in a randomized, double-blind, multicenter, and controlled phase III clinical trial.
Materials and methods
Recruitment of patients
This trial was performed at eight centers from October 2004 to December 2005 (clinical trial registration number: ChiCTR-TRC-00000093). The study protocol was evaluated and approved by their respective investigational and ethics committees. Five hundred three intention-to-treat (ITT) population RA patients (18 to 65 years old) who met revised American College of Rheumatology (ACR) criteria for the diagnosis of RA were entered into the study after giving their written informed consent . There are no patients in the phase II study who were enrolled in this phase III trial. Table 1 defines the study population. Admission criteria also included patients of either gender with RA with a duration of 6 to 24 months. Active RA was defined as the presence of at least three of the following criteria: six or more painful or tender joints, three or more swollen joints, morning stiffness for at least 45 minutes (on average during the week prior to entry), and an erythrocyte sedimentation rate (ESR) of at least 28 mm. Second-line agents were discontinued at least 4 weeks prior to entry. Continuous doses of NSAIDs were permitted. Patients to whom one of following applied were excluded: dysfunction of liver; severe cardiovascular, urinary, hematopoietic, or endocrine system disease; immunodeficiency; uncontrolled infection or active gastrointestinal tract disease; recent vaccination; gravida; women in lactation period or those recently intending to become pregnant; hypersensitivity to CII; treatment with any other disease-modifying anti-rheumatic drug within 30 days before enrolment; history of alcohol abuse; history of hyperglycemia or motor coordination disorder; or participation in other clinical trials within 3 months before enrolment.
The study was a two-to-one, eight-center, 24-week follow-up, double-blind, double-dummy, randomized, and MTX-controlled trial comparing efficacy and safety of CCII and MTX in the treatment of RA. Patients were randomly assigned to a CCII (n = 326) or MTX (n = 177) group that received either CCII (0.1 mg daily) or MTX (10 mg once a week). Patients and investigators were blinded to the treatment regimens throughout the study. Efficacy variables were assessed at 0, 12, and 24 weeks after administration of drug. Patients were allowed to remain on diclofenac sodium (50 mg daily), an NSAID. The diclofenac sodium dosage was not changed during the study. CCII capsules (#040328; Shanghai Materia Medica Bioengineering Institute, Shanghai, China), CCII dummy capsules, MTX tablets (#031201; Shanghai Xin Yi Pharmaceutical Factory, Shanghai, China), and MTX dummy tablets were obtained from Shanghai Materia Medica Bioengineering Institute. Patients were instructed to take oral CCII capsules or dummy capsules with 200 mL of cold water 30 minutes prior to eating breakfast every morning.
Flow sheet of production of chicken type II collagen
CCII is a protein extracted from the cartilage of chicken breast. Its molecular weight is 115 to approximately 135 kDa by SDS-PAGE electrophoresis method. In this study, the CCII capsule that patients received consisted of CCII and an adjuvant such as mannitol and glidantin. Figure 1 shows the flow sheet of production of CCII.
Clinical assessments of efficacy were made at baseline and repeated 12 and 24 weeks later. Efficacy variables included [21, 22] pain, and pain intensity was assessed by visual analogue scale (VAS) of 0 (no pain) to 10 (severe pain). Patients were questioned about the duration of morning stiffness experienced on the day before each study visit. Joint counts for tenderness and swelling were the sum of the number of affected joints. Physician and patient global assessments were rated according to VAS of 0 (very good) to 10 (very poor). Functional status was assessed at baseline and at 12 and 24 weeks using HAQ. ESR and C-reactive protein (CRP) values were obtained at baseline and at 12 and 24 weeks. Rheumatoid factor (RF) positivity was determined at the screening visit and at 24 weeks.
The primary efficacy variable was the ACR preliminary definition of improvement in RA . To reach improvement according to the ACR definition, a patient with RA must improve by at least 20% in tender and swollen joint count and by at least 20% in three of the five other measures: patient global assessment, physician global assessment, HAQ, acute-phase reactant, and patient pain assessment. In addition to the evaluation of 20% improvement (ACR-20), we determined RA improvement based on more substantial changes in RA core set measures, such as requiring at least 50% improvement (ACR-50) reported as secondary efficacy measures. The disease activity score using 28 joint counts (DAS28) was evaluated . Clinical parameters also included body weight, blood pressure, and heart rate. To standardize the evaluation of clinical variables, all investigators prior to study entry performed clinical evaluation of one patient with active RA.
At each visit, the patient was asked whether side effects were noticed during the interim. Side effects such as gastrointestinal complaints, vomiting, anorexia, headache, dizziness, insomnia, tetter, and mouth ulcers were known to occur frequently in treatment with CCII or MTX. Moreover, at entry and at 12 and 24 weeks, the following laboratory variables were assessed to monitor safety: complete blood cell count, serum levels of liver enzymes, creatinine, uric acid, and urinalysis.
Safety assessments were performed on all patients who consumed any masked study medication. Efficacy analyses were performed on the ITT population as well as on the population of patients who completed the 24-week study. Efficacy analysis of outcome variables was based on mean changes from baseline to endpoint in the ITT population. The data in Tables 1 and 2 and Figure 2 are expressed as mean ± standard deviation. The statistical software product used for these analyses was SAS, version 8.1 (SAS Institute Inc., Cary, NC, USA). All laboratory variables were subjected to descriptive statistics and compared by means of the Wilcoxon signed rank test. The randomization code was exposed only after the database was locked. Chi-square with Fisher exact test was used for categorical variables, and t analysis of variance was used for continuous variables. Significance level was established at 0.05.
Of 503 randomly assigned patients (326 in the CCII group and 177 in the MTX group), 49 patients withdrew early. Thirty (9.20%) patients withdrew in the CCII group, and 19 (10.73%) patients withdrew in the MTX group. There were various reasons for early withdrawal, such as adverse events, non-compliance, lack of response, and loss at follow-up. Three patients (0.92%) in the CCII group reported side effects, and five patients (2.82%) in the MTX group reported side effects. In the CCII group, three patients (0.92%) withdrew due to lack of compliance, and four patients (2.25%) withdrew because of non-compliance in the MTX group. Twelve (3.68%) and four (2.25%) patients in the CCII group and in the MTX group, respectively, withdrew because of lack of efficacy. Twelve and six patients in the CCII group and in the MTX group, respectively, were lost to follow-up. Four hundred fifty-four patients (296 in the CCII group and 158 in the MTX group) completed 24 weeks of therapy. There were no statistically significant differences between the two groups in terms of adverse events, non-compliance, lack of response, and loss at follow-up. At study entry, the two groups were well balanced with regard to demographic characteristics and disease parameters, and there were no statistically significant differences between the two groups in terms of gender, age, disease duration, body temperature, pain, morning stiffness, tender joint count, swollen joint count, HAQ, physician's assessment, patient's assessment, ESR, CRP, and RF (Table 1). Also, there were no important differences among the eight centers.
In both groups, there were decreases in pain, morning stiffness, tender joint count, swollen joint count, HAQ, and assessments of efficacy by both investigator and patient. Within-group differences (study entry versus 12 and 24 weeks) were statistically significant for the above clinical disease parameters (Table 2). At 12 weeks, there were statistically significant differences in morning stiffness, swollen joint count, HAQ, physician's assessment, and patient's assessment between the CCII group and the MTX group; there were statistically significant differences in pain, HAQ, and patient's assessment at 24 weeks between the two groups. In the MTX group, ESR and CRP decreased at 12 and 24 weeks, but changes in the two variables in the CCII group were not significant, and there was a statistically significant difference between the two groups. RF was not significantly affected by either drug therapy (Table 2).
American College of Rheumatology response criteria
Response rates for ACR-20 and ACR-50 were assessed at 12 and 24 weeks. With an ITT analysis (Figure 2), response rates for ACR-20 were 30.51% in the CCII group and 44.94% in the MTX group at 12 weeks. Response rates for ACR-50 were 8.81% and 15.03%, respectively. Response rates for ACR-20 were 41.55% in the CCII group and 57.86% in the MTX group at 24 weeks. Response rates for ACR-50 were 16.89% and 30.82%, respectively. Both response rates for ACR-20 and ACR-50 of the CCII group were lower than those of the MTX group. These changes were different to a statistically significant degree between the two treatment groups (P < 0.05).
Disease activity score using 28 joint counts
The DAS28 values of the two treatment groups were calculated (Table 3), and the results showed that the numbers of relief patients (≤ 2.6), low-activity patients (2.6 to approximately 3.2), mid-activity patients (3.2 to approximately 5.1), and high-activity patients (>5.1) were 36, 26, 138, and 96, respectively, in the CCII group at 24 weeks. In the MTX group, the numbers of relief patients, low-activity patients, mid-activity patients, and high-activity patients were 20, 19, 88, and 31, respectively. There was a statistically significant difference between the two treatment groups (P < 0.05).
All trials reported data about drug-related adverse outcomes in the ITT population. The majority of adverse outcomes were mild to moderate disturbances of the gastrointestinal tract. Gastrointestinal complaints were the most common adverse events. Other adverse events included vomiting, anorexia, headache, dizziness, insomnia, tetter, and mouth ulcers. These adverse events were mild and did not interfere with the continuation of treatment drugs (Table 4).
The analysis of adverse events was carried out on all 503 randomly assigned patients, and the adverse events of all patients were generally well tolerated. Adverse events were common in both groups. During the treatment period, the CCII group reported 18 (5.52%) adverse events whereas the MTX group reported 15 (8.47%) at 12 weeks. There were 18 (5.52%) adverse events in the CCII group and 17 (9.60%) adverse events in the MTX group at 24 weeks. There were fewer and milder side effects in the CCII group than in the MTX group (Table 5). The incidence of adverse events between the CCII group and MTX group was statistically significant (P < 0.05).
In the MTX group, there was a significant increase from baseline in transaminase and a decrease in white blood cell count. There were decreases in hemoglobin, platelet count, and neutrophil count in both groups, but the differences were insignificant (Table 4). Other laboratory variables were not significantly affected in the two groups.
Oral tolerance has been applied to prevent and treat autoimmune disease in several animal models, including arthritis. CII is the most abundant structural protein of human cartilage. The cartilage within the joint caused mainly damage of autoimmunity in patients with RA. CII autoimmunity may be a secondary phenomenon induced following inflammation in the joints and may play a role in the persistence of the disease rather than in actual induction of arthritis [25, 26]. In either case, downregulation of the immune response to CII may help prevent the resulting destructive arthritis. Oral administration of CII is an established procedure for inducing peripheral immune tolerance, which suppresses autoimmune responses in RA [27–29]. Bovine or chicken CII has been administered orally to RA patients, resulting in some clinical improvement. However, the precise mechanisms of oral tolerance are not fully known. Animal studies have revealed that the mechanisms of induction of oral tolerance include clonal deletion, suppression of the pro-inflammatory Th1 cells, and the induction of regulatory T (Treg) cells. Treg cells from Peyer's patches in the gut-associated lymphoid tissue and transforming growth factor-beta (TGF-β) are reported to mediate the induction of active suppression [8, 30]. Pro-inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor-alpha downregulate and suppressive cytokines such as TGF-β and IL-4 upregulate in oral tolerance. Treg cells, defined as a persistently CD25-expressing subset of CD4+ cells, may produce anti-inflammatory cytokines such as IL-10 and TGF-β and are likely to be agents of bystander suppression . In a basic study, investigators in our laboratory found that CCII plays an important role in regulating the immune balance of Th1/Th2 and Th17/Treg in rats with CIA. CCII decreases the overproduction of pro-inflammatory mediator (IL-2, IL-17) and increases the hypoproduction of anti-inflammatory mediator (IL-4, TGF-β). These results may support a mechanism of oral tolerance .
A key feature that may affect the induction of Treg cells and other suppressive mechanisms is the dose of antigen administered. A low dose of antigen stimulates the development of Treg cells, leading to an active immune suppression. The active mechanism appears to be a cytokine-mediated immune deviation with a predominant Th2 and Th3 response (TGF-β). In contrast, high-dose oral antigens lead to clonal deletion and anergy [33, 34]. The active suppression of low-dose oral tolerance can also suppress an unrelated immune response (bystander suppression), paving the way for therapy of autoimmune diseases . The results from human clinical trials suggest that a daily dose of significantly less than 1 mg is optimal. Similarly, data from CIA studies reveal an optimal dose above and below which there is little or no immune suppression. Indeed, the incorrect dose can prime the immune response and aggravate disease. The timing and frequency of administration are also vital to the level of immune tolerance induced and the control of the pathological process .
In a multicenter study, Barnett and colleagues  treated 90 RA patients with CCII for 12 weeks. Patients taking the lowest dose of CII (20 μg) had a 'significant' improvement in response rate compared with placebo-treated control patients (P < 0.035). Corrigall and Panayi  also reported a significant improvement in a group of RA patients treated with lyophilized CII. None of the patients in either study had significant side effects attributable to treatment with collagen. Similarly, Barnett and colleagues  previously reported that 8 of 10 juvenile RA patients had decreased numbers of swollen and tender joints after 3 months of treatment with CCII. Sieper and colleagues  administered bovine CII orally to patients with early RA for 12 weeks using doses of either 1 mg/day or 10 mg/day. More patients in the CII-treated groups met the ACR-20 and ACR-50 improvement criteria than did patients in the placebo group .
On the basis of the above, CCII was developed as a novel drug of immunologic tolerance. The present study was undertaken to further evaluate whether oral administration of CCII is safe and effective in patients with RA. In this phase III trial, CCII at 0.1 mg daily and MTX at 10 mg once weekly effectively alleviated signs and symptoms of active RA. However, the efficacy of CCII did not exceed that of MTX. The incidence of treatment-related adverse events was significantly different between the CCII group and the MTX group. According to the former study, CCII led to few adverse events in patients with RA . In this study, treatment was carried out in combination with diclofenac sodium, an NSAID, which can frequently cause gastrointestinal complaints. The use of diclofenac sodium can relieve pain. Nevertheless, its mechanism of action and toxicity can overlap with those of the trial drugs. The efficacy of CCII will be affected since diclofenac sodium can damage the alimentary system .
Above all, treatment of autoimmune diseases by induction of oral tolerance is attractive because of the few side effects and easy clinical implementation of this approach. The MTX-controlled, multicenter, 24-week trial in RA patients confirms that treatment with oral CII leads to improvement in arthritis and no significant side effects. These results are encouraging and imply that RA can be effectively treated with oral CII and partly supported the mechanism of oral tolerance. These data will provide a basis for more effective application of oral tolerance induction in RA patients. However, to clarify further the potential role and effectiveness of CCII as a toleragen in RA, ongoing studies and future work should clarify the autoimmune response to collagen in the pathogenesis of RA, and long-term observations in large numbers of patients need to confirm the efficacy of CCII and determine the optimal doses of orally administered CCII and which patients with autoimmune diseases will profit most from it.
In summary, the present study provides evidence in support of the potential efficacy and safety of CCII in patients with RA. CCII significantly improved joint function and exhibited better therapeutic efficacy and is safe for human consumption, even in the long term. This study provides important information about the efficacy and safety of CCII in the treatment of RA, and this information may be useful in promoting CCII as a promising alternative therapeutic strategy that may be used as a nutritional supplement against RA.
American College of Rheumatology
American College of Rheumatology 20% improvement criteria
American College of Rheumatology 50% improvement criteria
chicken type II collagen
type II collagen
disease activity score using 28 joint counts
erythrocyte sedimentation rate
health assessment questionnaire
non-steroidal anti-inflammatory drug
transforming growth factor-beta
visual analogue scale.
Turner DE, Helliwell PS, Woodburn J: Methodological considerations for a randomised controlled trial of podiatry care in rheumatoid arthritis: lessons from an exploratory trial. BMC Musculoskelet Disord. 2007, 8: 109-119. 10.1186/1471-2474-8-109.
Chung KC, Burns PB, Wilgis EF, Burke FD, Regan M, Kim HM, Fox DA: A multicenter clinical trial in rheumatoid arthritis comparing silicone metacarpophalangeal joint arthroplasty with medical treatment. J Hand Surg Am. 2009, 34: 815-823. 10.1016/j.jhsa.2009.01.018.
Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Griffin MR: Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007, 45: S66-76. 10.1097/MLR.0b013e318041384c.
Boyer JF, Cantagrel A, Constantin A: Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis. Curr Vasc Pharmacol. 2008, 6: 218-227. 10.2174/157016108784911975.
Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK: The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum. 2007, 57: 1151-1157. 10.1002/art.23003.
Maier E, Reipert BM, Novy-Weiland T, Auer W, Baumgartner B, Muchitsch EM: Induction of immune tolerance by oral IVIG. Int Immunopharmacol. 2007, 7: 351-359. 10.1016/j.intimp.2006.11.007.
Tsuji NM, Kosaka A: Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol. 2008, 29: 532-540. 10.1016/j.it.2008.09.002.
Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Fafard RD, Preuss HG: Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002, 22: 101-110.
Myers LK, Tang B, Rosioniec EF, Stuart JM, Kang AH: An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol. 2007, 27: 345-356.
Rowley MJ, Nandakumar KS, Holmdahl R: The role of collagen antibodies in mediating arthritis. Mod Rheumatol. 2008, 18: 429-441. 10.1007/s10165-008-0080-x.
Ding CH, Li Q, Xiong ZY, Zhou AW, Jones G, Xu SY: Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis. Clin Exp Immunol. 2003, 132: 416-423. 10.1046/j.1365-2249.2003.02167.x.
Trentham DE: Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Ann N Y Acad Sci. 1996, 778: 306-314. 10.1111/j.1749-6632.1996.tb21138.x.
Barnett ML, Combitchi D, Trentham DE: A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 1996, 39: 623-628. 10.1002/art.1780390413.
Barnett ML, Kremer JM, Trentham DE: Treatment of rheumatoid arthritis with oral type II collagen. Arthritis Rheum. 1998, 41: 290-297. 10.1002/1529-0131(199802)41:2<290::AID-ART13>3.0.CO;2-R.
Chen Q, Wei W: Effects and mechanisms of glucosides of chaenomeles speciosa on collagen-induced arthritis in rats. Int Immunopharmacol. 2003, 3: 593-608. 10.1016/S1567-5769(03)00051-1.
Zhang LL, Wei W: Therapeutic effects of glucosides of cheanomeles speciosa on collagen-induced arthritis in mice. Acta Pharmacol Sin. 2004, 25: 1495-1501.
Zheng YQ, Wei W, Shen YX, Dai M, Liu LH: Oral and nasal administration of chicken type II collagen suppresses adjuvant arthritis in rats with intestinal lesions induced by meloxicam. World J Gastroenterol. 2004, 10: 3165-3170.
Ju JH, Cho ML, Jhun JY, Park MJ, Oh HJ, Min SY, Cho YG, Hwang SY, Kwok SK, Seo SH, Yoon CH, Park SH, Kim HY: Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis. Immunol Lett. 2008, 117: 16-25. 10.1016/j.imlet.2007.09.011.
Zhang LL, Wei W, Xiao F, Xu JH, Bao CD, Ni LQ, Li XF: A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Rheum. 2008, 59: 905-910. 10.1002/art.23824.
Thompson DJ, Barron KS, Whitcup SM, Robinson MR: The safety and efficacy of chicken type II collagen on uveitis associated with juvenile rheumatoid arthritis. Ocul Immunol Inflamm. 2002, 10: 83-91. 10.1076/ocii.10.2.83.13977.
Vliet Vlieland TP, Zwinderman AH, Breedveld FC, Hazes JM: Measurement of morning stiffness in rheumatoid arthritis clinical trials. J Clin Epidemiol. 1997, 50: 757-763. 10.1016/S0895-4356(97)00051-6.
Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J: A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005, 52: 1360-1370. 10.1002/art.21018.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 727-735. 10.1002/art.1780380602.
Pincus T, Stein C: ACR-20: clinical or statistical significance?. Arthritis Rheum. 1999, 42: 1572-1576. 10.1002/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G.
Xi C, Tan L, Sun Y, Liang F, Liu N, Xue H, Luo Y, Yuan F, Sun Y, Xi Y: A novel recombinant peptide containing only two T-cell tolerance epitopes of chicken type II collagen that suppresses collagen-induced arthritis. Mol Immunol. 2009, 46: 729-737. 10.1016/j.molimm.2008.10.016.
Tanaka D, Kagari T, Doi H, Shimozato T: Administration of anti-type II collagen antibody sustains footpad swelling of mice caused by a delayed-type hypersensitivity reaction and induces severe arthritis. Clin Exp Immunol. 2007, 148: 360-367. 10.1111/j.1365-2249.2007.03354.x.
Cazzola M, Antivalle M, Sarzi-Puttini P, Dell'Acqua D, Panni B, Caruso I: Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo-controlled study. Clin Exp Rheumatol. 2000, 18: 571-577.
Myers LK, Higgins GC, Finkel TH, Reed AM: Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum. 2001, 44: 1775-1781. 10.1002/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V.
Choy EH, Scott DL, Kingsley GH, Thomas S: Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 2001, 44: 1993-1997. 10.1002/1529-0131(200109)44:9<1993::AID-ART347>3.0.CO;2-A.
Meyer O: Oral immunomodulation therapy in rheumatoid arthritis. Joint Bone Spine. 2000, 67: 384-392.
Min SY, Hwang SY, Park KS, Lee JS, Lee KE, Kim KW: Induction of IL-10-producing CD4+ CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II Collagen. Arthritis Res Ther. 2004, 6: R213-R219. 10.1186/ar1169.
Tong T, Zhao W, Wu YQ, Chang Y, Wang QT, Zhang LL, Wei W: Chicken type II collagen induced immune balance of Th subtypes in mesenteric lymph node lymphocytes in rats with collagen-induced arthritis. Inflamm Res. 2009
Faria AM, Weiner HL: Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006, 13: 143-157. 10.1080/17402520600876804.
Bäckström NF, Dahlgren UI: Bystander suppression of collagen-induced arthritis in mice fed ovalbumin. Arthritis Res Ther. 2004, 6: R151-R160. 10.1186/ar1150.
Oliveira CR, Taniguchi EA, Fusaro AE, Victor JR, Brito CA, Duarte AJ, Sato MN: Bystander effect in synergy to anergy in oral tolerance of Blomia tropicalis/ovalbumin murine co-immunization model. J Clin Immunol. 2005, 25: 153-161. 10.1007/s10875-005-2821-3.
Staines NA, Derry CJ, Marinova-Mutafchieva L, Ali N, Davies DH, Murphy JJ: Constraints on the efficacy of mucosal tolerance in treatment of human and animal arthritic diseases. Ann N Y Acad Sci. 2004, 1029: 250-259. 10.1196/annals.1309.056.
Corrigall VM, Panayi GS: Autoantigens and immune pathways in rheumatoid arthritis. Crit Rev Immunol. 2002, 22: 281-293.
Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA: Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum. 1996, 39: 41-51. 10.1002/art.1780390106.
Höer A, Gothe H, Schiffhorst G, Sterzel A, Grass U, Häussler B: Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf. 2007, 16: 854-858. 10.1002/pds.1387.
Gui-Jun Fei participated in the collection of data. This study was funded by Shanghai Materia Medica Bioengineering Institute and Shanghai Baolong Pharmacy Limited Company (Shanghai, China).
The authors declare that they have no competing interests.
WW contributed to the design of the project, served as the study coordinator, and helped to review the manuscript. LLZ contributed to the design of the project and was primarily responsible for writing the manuscript. JHX, CDB, LQN, XFL, YQW, LYS, RHZ, and BLS contributed to patient recruitment and management and to data collection. SQX, SL, WZ, JS, HXL, and RCW worked with patients to obtain informed consent, conducted clinical evaluations, took samples, and evaluated the therapeutic response to CCII. FX contributed to clinical data analysis. All authors read and approved the final manuscript.